BERLIN and HENNIGSDORF, GERMANY--(Marketwire - November 02, 2011) -
Revotar Biopharmaceuticals AG /
Revotar receives new composition-of-matter patent for Bimosiamose in the US
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
AG today announced that it has been granted a strategically important
a novel crystalline form of its pan-selectin antagonist Bimosiamose by the
Patent & Trademark Office (USPTO). This patent ("Crystalline Forms of 1,6-
US 8,039,601) covers a new polymorph form of the pan-selectin antagonist
pharmaceutical compositions and complements the patent portfolio which
is holding around this important product for the treatment of COPD and
chronic and acute respiratory diseases. It generates further composition-
matter for Bimosiamose and enhances the existing protection of the drug.
the life cycle of Revotar's most advanced drug candidate Bimosiamose on the
market the issuance of this patent is of strategic importance as it extends
protection of the compound beyond the existing intellectual property rights
until 2027", comments Dr. Martin Pöhlchen, CEO of Revotar. "We also
this patent qualifies as a basis for a patent term extension up to five
beyond 2027", he added.
Chronic Obstructive Pulmonary Disease (COPD) comprises several serious
conditions affecting the lung. According to the WHO, estimated 64 million
have COPD worldwide in 2004. More than 3 million people died of COPD in
which corresponds to 5% of all deaths globally. The WHO predicts that COPD
become the third leading cause of death worldwide by 2030. In 2010, the
COPD market recorded sales of approximately 11 billion US$. There is a high
unmet medical need in drugs modifying the underlying inflammation in COPD.
About Revotar Biopharmaceuticals AG
Revotar recently announced that it successfully completed a multi-center
II trial to evaluate the safety and efficacy of inhaled Bimosiamose for the
treatment of patients with chronic obstructive pulmonary disease (COPD).
Data have been presented in the late breaking news session at the recent
congress of the European Respiratory Society (ERS) in Amsterdam end of
and were presented by the research group of Prof. Helgo Magnussen. As
released, inhalation of Bimosiamose for 28 days on top of standard
bronchodilators was safe and well tolerated in 77 patients with moderate to
severe COPD (GOLD II-III). It led to a broad and significant attenuation of
airway inflammation and a trend towards lung function improvement.
Revotar develops innovative drugs for inflammatory indications such as
obstructive pulmonary disease (COPD), acute lung injury (ALI) and asthma.
lead candidate Bimosiamose, a pan-selectin antagonist, has already passed
several clinical phase I and phase IIa trials in COPD, asthma, and
with a good safety and efficacy profile in over 300 patients and
Furthermore Revotar has two preclinical programs addressing respiratory and
other inflammatory diseases.
Press Release (PDF) :
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Revotar Biopharmaceuticals AG via Thomson Reuters ONE